Latest / Pharmacy Podcast Network / PhARM-OUD Guidelines: Buprenorphine & Community Pharmacies| Pain Pod
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:23Speaker 2: This is the Pain Pod. You want to see pain
- 0:28Speaker 2: look at me?
- 0:35Speaker 3: Welcome to the Pain Pod, the podcast for all things
- 0:40Speaker 3: pain management, hosted by the Pain Guy.
- 0:44Speaker 2: Doctor Mark Grow.
- 0:49Speaker 3: We'll be collaborating with numerous pain management experts talking about
- 0:53Speaker 3: substance usage disorders, the latest treatment modalities, and the most
- 0:58Speaker 3: important focusing on the pain of our patients as leading
- 1:02Speaker 3: providers of pain care. And now here's our host, a
- 1:09Speaker 3: man wanted in all fifty states, a suburban city like
- 1:14Speaker 3: Mountain Man without the beard, from the hills of West
- 1:18Speaker 3: Virginia and certified in weapons.
- 1:22Speaker 2: Of mass destruction response.
- 1:25Speaker 3: It is doctor Mark or boy.
- 1:35Speaker 1: All right, welcome and welcome back everyone to the Pain
- 1:38Speaker 1: Pod here on the Pharmacy Podcast Network. So, yeah, you
- 1:41Speaker 1: know yours truly here is says quote unquote pain Guy.
- 1:45Speaker 1: You know, we want to go into the frontiers and
- 1:47Speaker 1: talk about the things that are out there improving and
- 1:51Speaker 1: saving lives. Right, it's pain management, of course, but you know,
- 1:55Speaker 1: transcending well beyond that, and there's a lot of times
- 1:58Speaker 1: when the conversations go with pain management and substitute disorder addiction.
- 2:02Speaker 1: And today we're going into that frontier, okay, And I
- 2:06Speaker 1: think we have a treat in store with one of
- 2:09Speaker 1: the national experts underlying italic bold font pick a color
- 2:13Speaker 1: two and all of that here with doctor Tyler of Arisco.
- 2:18Speaker 1: And I certainly want to welcome you Tyler here to
- 2:20Speaker 1: the paint pod. Today we'll be going over the pharmal
- 2:23Speaker 1: unique guidelines. But first up, welcome aboard, sir.
- 2:28Speaker 2: Thanks Mark. And the term expert makes me uncomfortable because
- 2:33Speaker 2: then I know things, So I guess I can introduce myself.
- 2:37Speaker 2: So my name is Tali Risco. I am a pharmacist
- 2:40Speaker 2: by training. I worked in community pharmacies for about ten
- 2:44Speaker 2: years as a technician and then as a practicing pharmacist,
- 2:47Speaker 2: mainly in the independent setting, and I think that that's
- 2:50Speaker 2: kind of important to the way that I will get
- 2:52Speaker 2: research questions now. But somewhere along the way, I decided
- 2:55Speaker 2: to do a PhD. And so I got my PhD
- 2:58Speaker 2: and Pharmaceutical Health Outcomes and POUL from the University Houston
- 3:01Speaker 2: College of Pharmacy. My training mainly focused on pharm cop
- 3:06Speaker 2: and emiology and health services research, and then After that,
- 3:11Speaker 2: I stayed at the University of Houston as an assistant
- 3:13Speaker 2: professor and am now the assistant director of our Prescription
- 3:18Speaker 2: Drug Misuse Education and Research or Premier Center here in
- 3:22Speaker 2: the College of Pharmacy. And as you said earlier, we
- 3:25Speaker 2: mainly focus on issues surrounding the management of substance use disorder,
- 3:30Speaker 2: with a heavy emphasis on opioid use disorder, and a
- 3:34Speaker 2: lot of what I do focus is on making treatment
- 3:37Speaker 2: more accessible in the community setting, although we were also
- 3:41Speaker 2: doing some work in the transitions of care space for
- 3:43Speaker 2: patients who are admitted to the impatient side, but we
- 3:47Speaker 2: mainly focus on community access and what can we do
- 3:50Speaker 2: to improve the quality of care for this population. So
- 3:53Speaker 2: thanks for having me today. I'm looking forward to the discussion.
- 3:55Speaker 1: Oh absolutely, as always, you know, it's always good when
- 3:59Speaker 1: it's not just colleagues and all that too. So well, yeah,
- 4:04Speaker 1: and I know you work alongside uh doctor Doug Thornton,
- 4:07Speaker 1: of course.
- 4:08Speaker 2: Yeah, Doug. Doug was my advisor and we're still very
- 4:11Speaker 2: close collaborators today. He's been a tremendous mentor and a
- 4:16Speaker 2: tremendous colleague. You know, we've we've published a lot together,
- 4:19Speaker 2: and I know you know him as well.
- 4:22Speaker 1: Oh yeah, he's he's had his time at w Wild
- 4:24Speaker 1: and Wonderful West Virginia of course. Uh oh, good times
- 4:28Speaker 1: back in the day right well here today.
- 4:32Speaker 2: Though, both mountaineers. He owns it, yes, yes, where's.
- 4:36Speaker 1: It at sleep So he's one of those that I
- 4:39Speaker 1: could joke about where it's like, oh well I went
- 4:41Speaker 1: to pitt and I work at w W and uh,
- 4:43Speaker 1: all those of you across the country, particularly East coast,
- 4:46Speaker 1: you might be uh, you always wonder right, it's like
- 4:48Speaker 1: walking backyard brawl. Turns out I'm not the only one though,
- 4:51Speaker 1: So all right, So you know, you mentioned a lot
- 4:53Speaker 1: of dynamic efforts, as I would call it, at least
- 4:57Speaker 1: that you know, your center dives into. And I think
- 5:00Speaker 1: it's very very important to recognize folks that, you know,
- 5:04Speaker 1: when we read of research and a lot of folks
- 5:07Speaker 1: you know, being real, will be like, oh well yeah,
- 5:09Speaker 1: but that guy or galap did they ever worked the bench?
- 5:12Speaker 1: Well here you go. You got somebody here that did, right,
- 5:15Speaker 1: and you know, like yours truly actually it's not today,
- 5:18Speaker 1: but you know it's like riding a bike, right. That
- 5:21Speaker 1: being said, though, things do change over time, but it's
- 5:24Speaker 1: very good to have that informing you know, effort from
- 5:28Speaker 1: the past. Of course, so here today what we really
- 5:31Speaker 1: want to hone in on is, you know, the the
- 5:34Speaker 1: buepnorphying guidelines overall when it comes to community pharmacies, but
- 5:38Speaker 1: you know the longer name of course, pharmacy access to
- 5:41Speaker 1: Resources and Medication for Opioid Use Disorder or the formal
- 5:45Speaker 1: UD guideline. I certainly appreciate Tyler, you know, back in
- 5:49Speaker 1: the day being invited to be a part of the process,
- 5:52Speaker 1: part of the effort overall. And you know, a journey
- 5:56Speaker 1: of one thousand miles begins with a single step. Gosh,
- 5:59Speaker 1: I'm channeling my vallectorian speech back in the day in
- 6:02Speaker 1: high school. And turns out there's so many pharmacists that
- 6:05Speaker 1: have been those same shoes. But you know that's that
- 6:07Speaker 1: single step. Like where did where did this start? Like
- 6:10Speaker 1: where did the pharmaed guidelines?
- 6:12Speaker 2: Where? Where?
- 6:12Speaker 1: What was the drive? Where did it all start?
- 6:15Speaker 2: Yeah, that's a great question. So it really started because
- 6:20Speaker 2: I wanted to make you do more work and I
- 6:24Speaker 2: needed to rope you into something. Now where this started
- 6:28Speaker 2: is very much so sort of in in community practice,
- 6:32Speaker 2: and so you know, I.
- 6:35Speaker 4: Had been working in treatment for a couple of years,
- 6:39Speaker 4: and we had published several healthcare quality studies that were
- 6:44Speaker 4: really looking at the process of care for patients with OPI.
- 6:47Speaker 2: Wo had used to sort of in the community setting.
- 6:49Speaker 2: And one of those studies we actually identified that in
- 6:52Speaker 2: the Texas Prescription Drug Monitoring Program that about twenty five
- 6:56Speaker 2: percent of our patients who initiated bepron orphan had to
- 6:58Speaker 2: change pharmacies within the six months of treatment, and that
- 7:02Speaker 2: when they changed, their likelihood of a gap in therapy
- 7:04Speaker 2: of seven days or more increased by about one point
- 7:08Speaker 2: six seven times. And so you know, if you know
- 7:11Speaker 2: a little bit about op you had used disorder, you
- 7:14Speaker 2: know that any gap in medication possession dramatically increases risk
- 7:18Speaker 2: of mortality, may may as much as double or even
- 7:21Speaker 2: more depending on the estimate risk of mortality for those patients.
- 7:24Speaker 2: And so that really started this question of, well, why
- 7:28Speaker 2: are they changing pharmacies so frequently? Number one? And number two,
- 7:32Speaker 2: what can we do to keep them in one place
- 7:34Speaker 2: and ensure that they are receiving the care that they need.
- 7:36Speaker 2: And also around this time, Lucas Hill, who's now at
- 7:40Speaker 2: pitt but was at the University of Texas and some
- 7:43Speaker 2: other folks were starting to publish papers that showed that
- 7:46Speaker 2: only about a half to sixty percent of all community
- 7:49Speaker 2: pharmacies were actually carrying bupern orphan products. And there were
- 7:54Speaker 2: some other papers that came out around that time that
- 7:57Speaker 2: sort of suggested that, you know, their stigma at play
- 8:00Speaker 2: from the pharmacy workforce, or there were issues purchasing dupern orphan.
- 8:05Speaker 2: And I think that those are all valid answers, But
- 8:08Speaker 2: what we really wanted to do is not figure out
- 8:11Speaker 2: I guess what the barriers were, but how do we
- 8:13Speaker 2: actually go about addressing those barriers. And I think what
- 8:16Speaker 2: it comes down to, and you and I have talked
- 8:17Speaker 2: about this, is there's just a gap of training surrounding
- 8:22Speaker 2: sort of the administrative aspects of providing care to either
- 8:26Speaker 2: patients with pain or patients with opio use disorder. And
- 8:31Speaker 2: if you look at the available guidelines from SAMSA or
- 8:34Speaker 2: from ASAM, they provide great clinical advice, but there's not
- 8:38Speaker 2: a lot of practical administrative guidance on, you know, setting
- 8:43Speaker 2: up your addiction practice as a community pharmacist, and how
- 8:47Speaker 2: do we actually make sure that this service line is
- 8:49Speaker 2: integral to our pharmacy model. That's just not there, and
- 8:52Speaker 2: you wouldn't expect it to be there, because those guidelines
- 8:54Speaker 2: are made for physicians, they're made for prescribers. And so
- 8:58Speaker 2: we went to the Foundation for Opioid Response Efforts and
- 9:01Speaker 2: we suggested that a way to sort of get around
- 9:05Speaker 2: some of these barriers to care in the community pharmacy
- 9:07Speaker 2: setting would be to create targeted guard guidance for community
- 9:12Speaker 2: pharmacists that goes beyond the clinical and also addresses the administrative,
- 9:17Speaker 2: the wholesale, the regulatory, as well as sort of applies
- 9:22Speaker 2: and defines corresponding responsibility in the setting of care for
- 9:26Speaker 2: patients with opioid use disorder. So what we came up
- 9:30Speaker 2: with through this four round Delphi process was a series
- 9:35Speaker 2: of nine recommendations and several supporting recommendations that sort of
- 9:40Speaker 2: put some nuance on our knowledge of diversion control, on
- 9:45Speaker 2: our knowledge of stigma and the community setting, and take
- 9:49Speaker 2: these principles and guide them toward the over our jingle
- 9:52Speaker 2: of making sure that we are dispensing necessary prescriptions for
- 9:56Speaker 2: patients with opioid use disorder. And so really this just
- 10:00Speaker 2: guarded from a place of needing guidance that spoke to
- 10:03Speaker 2: the pharmacy workforce, and I hope that its sparks additional
- 10:07Speaker 2: guidance creation and other disease states that we often see
- 10:09Speaker 2: in the community setting as.
- 10:10Speaker 1: Well, wonderful efforts overall. Right, and well, you know, I
- 10:16Speaker 1: don't want to jump ahead here and kind of you know,
- 10:18Speaker 1: chicken before the egg or vice versa. But before covering
- 10:22Speaker 1: some of these faces here, what do you think, you know, like,
- 10:25Speaker 1: what's the next steps for you know, the the overall
- 10:28Speaker 1: efforts here with the form OD guidelines.
- 10:31Speaker 2: Yeah, that's a great question. So one of my biggest
- 10:34Speaker 2: fears is that this document just sits on the.
- 10:36Speaker 1: Shelf, right, so we don't len it.
- 10:41Speaker 2: So that's what we're trying to do. We're trying to
- 10:43Speaker 2: make sure that we actively disseminate it to the workforce.
- 10:46Speaker 2: We've had some conference presentations, we've put together some continuing
- 10:49Speaker 2: professional education and that can all be access in the
- 10:53Speaker 2: NCPA Learning Center, and then there's some additional programming from
- 10:56Speaker 2: the Premier Center that's available for free as well. You know,
- 11:00Speaker 2: we've really to this day focused on how do we
- 11:04Speaker 2: disseminate effectively and so one of the pathways that we
- 11:07Speaker 2: really hope to take is by using patients to help
- 11:10Speaker 2: us disseminate and so right now we have a patient
- 11:14Speaker 2: Steering Committee that we've been paneled, and they are helping
- 11:17Speaker 2: us sort of create tailored guidance for other patients to
- 11:22Speaker 2: help them advocate for themselves at the pharmacy counter. And
- 11:26Speaker 2: part of that patient toolkit that we're putting together is
- 11:31Speaker 2: hopefully going to be some information on how to obtain
- 11:36Speaker 2: technical assistance or support for their pharmacists. And so we
- 11:40Speaker 2: want patients to be able to steer pharmacists back to
- 11:43Speaker 2: us or to let us know when you know, they
- 11:47Speaker 2: have had an issue with a pharmacist and need for
- 11:50Speaker 2: their guidance, so we can intervene and offer support for
- 11:52Speaker 2: that pharmacist to make sure that they are providing care.
- 11:55Speaker 2: So sort of patient directed academic detailing is one component,
- 12:00Speaker 2: but the other component too is you know, we're always
- 12:02Speaker 2: available to answer questions. And I know that there are
- 12:06Speaker 2: a couple of Abatement funded programs that are distributing our
- 12:10Speaker 2: guidance as part of academic detailing efforts for the pharmacy
- 12:15Speaker 2: workforce in their state, and we want to support those
- 12:17Speaker 2: initiatives as best as we can. And I tell people
- 12:22Speaker 2: this all the time. If you open the first page
- 12:23Speaker 2: the guideline or download it and look at the cover page.
- 12:27Speaker 2: My email address and my phone number are on that
- 12:30Speaker 2: first page, and we're always available to answer questions. And
- 12:33Speaker 2: we hope to continue to be able to fund technical
- 12:35Speaker 2: assistance and support services for the pharmacy workforce to make
- 12:39Speaker 2: sure that we can continue to answer those questions and
- 12:41Speaker 2: continue to keep the guidance alive and informing care.
- 12:45Speaker 1: Wonderful efforts really both. You know, it's patient. I mean
- 12:49Speaker 1: the patient gets particularly a patient and pain quite frankly,
- 12:52Speaker 1: but or you know, patient with hope, you you disorder,
- 12:55Speaker 1: so on and so forth. You know, there's words like
- 12:58Speaker 1: marginalized and there's just lost in the shuffle many times.
- 13:01Speaker 1: So it's incredible to hear that, you know, incorporating patients
- 13:04Speaker 1: along the way, because guess what, folks, Hey, we end
- 13:07Speaker 1: up being patients too. So you know, there's at least
- 13:09Speaker 1: that it's it's like geriatric here, like oh, I've had
- 13:11Speaker 1: folks be like, oh, well why do you why'd you
- 13:13Speaker 1: get specialized in that? I'm like, well, yeah, there's many reasons.
- 13:16Speaker 1: But conversationally it's well, you know, the goal is to
- 13:19Speaker 1: become one, right, Yeah, that's kind of one of the
- 13:22Speaker 1: end goals anyway. But anyways, you know, when putting on
- 13:25Speaker 1: the shoes, it's really important there too, So yeah, and folks,
- 13:28Speaker 1: if you you know, as far as this guideline, we
- 13:31Speaker 1: always have things in the show notes for the podcast
- 13:33Speaker 1: here in the pain Pod, of course, but you could
- 13:35Speaker 1: always always go to paining Guy dot us. This guideline
- 13:38Speaker 1: is there, just to click on the resources tab. It's
- 13:40Speaker 1: been there since publication quite frankly, so feel free to
- 13:45Speaker 1: you know, navigate there or hey, doctor Google will work
- 13:48Speaker 1: out too, of course.
- 13:50Speaker 2: Yeah, and you know, always you can always email me
- 13:53Speaker 2: and we've we've answered questions from a lot of pharmacists
- 13:56Speaker 2: around the country now on wholesale issues and in particular
- 14:00Speaker 2: or issues with surrounding corresponding responsibility. And if I don't
- 14:05Speaker 2: know the answer to a question or can't help you
- 14:07Speaker 2: out directly, I can certainly connect you to one of
- 14:09Speaker 2: the authors of guidance who has some expertise in that area.
- 14:12Speaker 2: And so far people have been very willing to communicate.
- 14:16Speaker 2: And I do just want to mention that another area
- 14:18Speaker 2: that we're working in now, and we have a paper
- 14:21Speaker 2: under review. We're also working on ways to improve bupern
- 14:24Speaker 2: orphan wholesale, and I think we'll get into this here
- 14:26Speaker 2: in a little bit with some discussion surrounding the opioid settlement,
- 14:29Speaker 2: but we have a companion document that's hopefully coming out
- 14:32Speaker 2: very soon on ways that buper and orphan distributors can
- 14:38Speaker 2: ensure that they are meeting the needs of pharmacists. And
- 14:42Speaker 2: you know, I do think that there is still stigma
- 14:44Speaker 2: in the pharmacy workforce. I'm not saying that there's not,
- 14:46Speaker 2: but I do think that pharmacists are being honest a
- 14:48Speaker 2: lot of the time when they say that they just
- 14:50Speaker 2: can't order these drugs and they can't provide care because
- 14:53Speaker 2: their distributor has thresholds and they're crossing these thresholds, or
- 14:57Speaker 2: they have to prioritize their pain or their hospice patients
- 15:00Speaker 2: so they can't purchase pepern orphan. And I understand that
- 15:04Speaker 2: we want to do what we can to also make
- 15:06Speaker 2: sure that the distributors and that the state Prescription Monitoring
- 15:08Speaker 2: Program administrators and the Board of Pharmacy are also doing
- 15:12Speaker 2: what they can to improve access. So I don't advocate
- 15:16Speaker 2: for anything because I'm a public school teacher in Texas,
- 15:20Speaker 2: but what I do do is I like to educate
- 15:22Speaker 2: policymakers and other stakeholders when I can to ensure that
- 15:25Speaker 2: we're doing everything that is possible to ensure that there
- 15:29Speaker 2: is a safety net for people that are living with
- 15:31Speaker 2: opioid use disorder other substance use disorders.
- 15:34Speaker 1: You know, I can appreciate when talking about one guideline,
- 15:37Speaker 1: you know, the form oed like we're here today, but
- 15:41Speaker 1: you know, other things certainly not even a guideline, but
- 15:43Speaker 1: I'll surely take the invite there for the National avoid
- 15:45Speaker 1: Settlement conversation. I'm sure there's others like CDC guidelines and
- 15:49Speaker 1: all that as well, too different realm. But you know,
- 15:52Speaker 1: I often wonder, you know, there's the National a Fioid
- 15:55Speaker 1: Settlement literally or National Opioid Settlement dot com. Know, you
- 16:01Speaker 1: land on a good amount of seven hundred page documents,
- 16:05Speaker 1: so it's not like you just see a billboard when
- 16:07Speaker 1: you go there, by the way, but the information within
- 16:10Speaker 1: is very important. It's it's the most granular controlled substance
- 16:16Speaker 1: red flags descriptions that I've ever seen, pretty much anybody's
- 16:20Speaker 1: ever seen, because they're very granular, very specific. Along the
- 16:23Speaker 1: way that being said, most folks wouldn't realize that you know,
- 16:27Speaker 1: when they list prescription opia it's out. They literally say
- 16:32Speaker 1: that list does not include any concerns with upenorphine. And
- 16:37Speaker 1: I find that very interesting that not many folks know
- 16:40Speaker 1: that because you know, conversations, Gosh, Tyler, you've had more
- 16:43Speaker 1: than me, even with pharmacists all across the country in
- 16:46Speaker 1: different settings. But you know, we're usually honing in like
- 16:48Speaker 1: community in general, and you know, concerns with stalking it,
- 16:52Speaker 1: concerns with having it the thresholds like you mentioned earlier
- 16:55Speaker 1: with the wholesale distributors. But here, you know, we have
- 16:58Speaker 1: there's the overall national settlement. And they came right out
- 17:01Speaker 1: and said, you know, hey, red flags will happen, mitigate
- 17:05Speaker 1: them and document it. And they also came right out
- 17:07Speaker 1: and said, yeah, buep and orphan is not even on
- 17:09Speaker 1: the spectrum here. Any thoughts on that or things you'd
- 17:13Speaker 1: want to amplify and talk about with folks here.
- 17:16Speaker 2: Yeah, So I'm assuming you're referring to the agreement with
- 17:20Speaker 2: pharmacy chains in particular. Yes, yes, yeah, And so that's
- 17:26Speaker 2: that's a great point. So buper orthan is omitted from
- 17:30Speaker 2: the agreement with pharmacy chains, and I think that that
- 17:32Speaker 2: was a wise public health decision, but that agreement was
- 17:35Speaker 2: settled later than the agreement with the distributors, and so
- 17:40Speaker 2: one of the issues that we are trying to work
- 17:43Speaker 2: around now is that if you look at Exhibit P,
- 17:46Speaker 2: the injunctive relief agreement between distributors in the States that
- 17:49Speaker 2: was broken by the Department of Justice, one of the
- 17:53Speaker 2: things in that agreement that is concerning is that bupern
- 17:56Speaker 2: orthan without the lock zone is listed as an usual formulation,
- 18:03Speaker 2: and the agreement then goes on to provide some parameters
- 18:06Speaker 2: for unusual formulations and even details certain approaches to identifying
- 18:12Speaker 2: red flags for these prescriptions. And one of the issues, however,
- 18:18Speaker 2: that you do rightfully point out, is that the agreement
- 18:21Speaker 2: makes it very very clear that drugs should be regulated
- 18:24Speaker 2: within family and so recommendations for unusual formulations such as
- 18:32Speaker 2: buper and orthan without moloxome should not necessarily apply to
- 18:37Speaker 2: buepernorthan with nooxone, as the agreement makes it very clear
- 18:40Speaker 2: that we're talking about products without innoxon. And I'm a
- 18:44Speaker 2: big proponent of access to buepern orthan monotherapy. I think
- 18:48Speaker 2: there are a lot of patients, particularly those on higher
- 18:50Speaker 2: doses of buperorthan, or those who are pregnant potentially although
- 18:54Speaker 2: the evidence is somewhat wish you wash you there, or
- 18:58Speaker 2: you know, patients that potentially have had some dental issues
- 19:01Speaker 2: or can't afford combination therapy, whatever it is. I think
- 19:04Speaker 2: there's a role for buper orphan monotherapy and that's the guidance.
- 19:06Speaker 2: But if you look at this from a wholesale perspective,
- 19:12Speaker 2: we shouldn't have the restrictions on combination products that we do.
- 19:16Speaker 2: And I think that the reason that we do have
- 19:19Speaker 2: issues with distributors is that a lot of these suspicious
- 19:23Speaker 2: order reporting programs that have been developed by the distributors
- 19:27Speaker 2: tend to sort of roll all buper and orphan products
- 19:30Speaker 2: together in that category. And we hear this a lot
- 19:32Speaker 2: from pharmacists that if I cross my buper and orthan
- 19:36Speaker 2: combination threshold or my mono threshold, I can't order any
- 19:40Speaker 2: other buper and orphan products, or more extremely, if I
- 19:43Speaker 2: cross any opioid threshold in any given month, I can't
- 19:46Speaker 2: order more buper and orthan. And so I question whether
- 19:50Speaker 2: or not the suspicious order reporting systems that are in
- 19:53Speaker 2: place actually do adequately differentiate between buper and orthan monoproduct
- 19:58Speaker 2: buper and orphan combination product and other opioids, and I
- 20:02Speaker 2: and many others strongly suspect that the way that these
- 20:05Speaker 2: programs are actually designed is that they just roll all
- 20:08Speaker 2: opioids together and make it really, really hard for pharmacists
- 20:11Speaker 2: to meet the evolving care needs of their patient population.
- 20:15Speaker 2: One thing that we hear a lot from pharmacists is,
- 20:18Speaker 2: you know, I really want to do this. I tried
- 20:21Speaker 2: to form a relationship with a treatment provider in my area.
- 20:24Speaker 2: We made it about two weeks, then I crossed my
- 20:26Speaker 2: threshold and I was done for a month. Well, I
- 20:29Speaker 2: don't see a reason that that has to happen in
- 20:31Speaker 2: the injunctive relief, and I really hope that we see
- 20:33Speaker 2: some action from either DEA or DOJ or HHS more
- 20:38Speaker 2: broadly to inform the distributors of their obligation to ensure
- 20:42Speaker 2: that actual clinical needs if patients are met, rather than
- 20:45Speaker 2: just to prevent diversion.
- 20:49Speaker 1: You know, if it was the first time I heard,
- 20:51Speaker 1: I think I'd be TechEd kardic through the roof by now.
- 20:53Speaker 1: With this whole monel versus combo products.
- 20:56Speaker 2: For yeah product, it's go.
- 21:00Speaker 1: And I have had that's never enough conversations on it.
- 21:03Speaker 1: But we've also been in rooms and scenarios where people
- 21:07Speaker 1: are talking the opposite of the pharmacological facts, and the
- 21:10Speaker 1: eyebrows at least four of them go up to yours
- 21:12Speaker 1: and mine and anybody else sitting next to us, you know,
- 21:16Speaker 1: along the way, and it's it's just so concerning where
- 21:20Speaker 1: you know, and you articulate very well earlier Tyler and
- 21:23Speaker 1: the you know, the bigger picture efforts here for the
- 21:25Speaker 1: farm D guidelines overall of you know, how to address things.
- 21:31Speaker 2: Along the way.
- 21:32Speaker 1: A lot of things do come back to the pharmacology.
- 21:34Speaker 1: And you know, I've always got to rock out my
- 21:35Speaker 1: inner nerd. Here turns out, folks, if you're since you're listening,
- 21:39Speaker 1: you're right there with us too, right, you know, there's
- 21:43Speaker 1: serious ExM. There's YouTube, and then there's the pain pod. Right,
- 21:47Speaker 1: it's when you click the button. We all kind of
- 21:50Speaker 1: self identify there of love and the pharmacology and the
- 21:52Speaker 1: nerdy side of things. But you know, the solo products there,
- 21:55Speaker 1: it's comes on to cost and it's a street rap
- 21:58Speaker 1: as well. You know, you already mentioned the dental concerns
- 22:00Speaker 1: for combo product formulations, not the medicine, but the formulations,
- 22:04Speaker 1: the parvnancy side of things, where there's two years ago
- 22:07Speaker 1: that was at least half a dozen articles out there
- 22:09Speaker 1: explaining how that's I'll back up the as you said,
- 22:12Speaker 1: the wishy washy is part there. You know, the cost
- 22:15Speaker 1: is it depends on the supply chain. In the healthcare
- 22:18Speaker 1: supply chain, that's where we roll with licenses. It's the
- 22:22Speaker 1: cheapest versions out there, the solo ingrading products. That is
- 22:26Speaker 1: when you look to the streets supply that's you know,
- 22:29Speaker 1: get into a tricky area. But you know, there's still
- 22:32Speaker 1: that falsehood out there that it's like, oh, well, that's
- 22:36Speaker 1: you know, a perception of oh that's the better one
- 22:38Speaker 1: or whatever. And it's like, this is the first time
- 22:39Speaker 1: in the history of mankind that us, you know, fancy
- 22:43Speaker 1: educated degree people in healthcare have the opportunity to educate
- 22:49Speaker 1: everyone outside of that, usually it's we need to shush,
- 22:52Speaker 1: listen and learn. Here here's one where we could actually
- 22:55Speaker 1: help out too, write And it comes down to that
- 22:57Speaker 1: pharmacology as well. So thank you, thank you for bringing that.
- 23:00Speaker 1: It's one I always I never hesitate. Y'all know me
- 23:04Speaker 1: by now, But.
- 23:06Speaker 2: Can I tell a funny story, please. So I was
- 23:11Speaker 2: given a local presentation to our college's dean's advisory Board,
- 23:15Speaker 2: and we had a faculty member who's been there for
- 23:18Speaker 2: you know, a few decades and he's retiring. His name
- 23:21Speaker 2: is Richard Bond, and he's a great cardiovascular pharmacologist and
- 23:26Speaker 2: I mean made significant contributions to beta blockade, and he has
- 23:31Speaker 2: had just a phenomenal career in pharmacology. And I'm I'm
- 23:34Speaker 2: talking about some of these issues, you know, surrounding bupern
- 23:37Speaker 2: orphan and public reception of bupern orphan and and and
- 23:43Speaker 2: some of the regulation behind it. And after the presentation,
- 23:45Speaker 2: doctor Bond comes up to me and he's, you know,
- 23:48Speaker 2: he's familiar with the pharmacology of buper orphan, but not
- 23:52Speaker 2: familiar with the regulation of buper orphan. And he comes
- 23:54Speaker 2: up to me and he goes, this is crazy. It's
- 23:56Speaker 2: a partial agonist. Why do they care? We what is
- 23:59Speaker 2: anybody gonna do with it? It's not fun, It's it's
- 24:02Speaker 2: not abuse, Sleigh Ayle, It's a partial agonist. What what's
- 24:05Speaker 2: all the fuss that this is unnecessary? And I said,
- 24:08Speaker 2: I couldn't agree more. So, you know, there there is
- 24:11Speaker 2: a lot of pharmacology just doesn't support here.
- 24:16Speaker 1: Yeah, it's a it's amazing quite frankly, and that's a word. Yeah,
- 24:24Speaker 1: it's you know, most people hear partial agonists and you
- 24:27Speaker 1: think it's the whimp in the room. It's like, oh,
- 24:29Speaker 1: it only kind of like partial jeepers. I really appreciate
- 24:33Speaker 1: that story. Actually, you know, it's not an outside perspective.
- 24:37Speaker 1: That's you know, pharmacy professional one of one of us, right,
- 24:41Speaker 1: Oh yeah, you know typically I used to a different
- 24:44Speaker 1: genre of care and it's you know that that that
- 24:46Speaker 1: you know, big voice in the room to say, what
- 24:48Speaker 1: what's going on? Guys, like what what's all the fuss? Geez, wonderful?
- 24:53Speaker 1: Well one of the so Tyler. One of the the
- 24:56Speaker 1: other I guess recent or current themes out there is
- 24:59Speaker 1: this the conversation on the you know, the potential utilization
- 25:03Speaker 1: of higher MOUD doses, particularly with bupan orphine. You know
- 25:09Speaker 1: the FDA labeling it's you know, approved up to twenty
- 25:12Speaker 1: four milligrams for the longest time. There's a lot of
- 25:15Speaker 1: consternation on like eight or sixteen and then all the
- 25:17Speaker 1: way to twenty four. But you know that drug supply
- 25:19Speaker 1: has changed. There's a lot going on I don't want
- 25:22Speaker 1: to pull every concept out of the conversation within my question,
- 25:27Speaker 1: but what's some thoughts or experiences via you've had in
- 25:30Speaker 1: that realm.
- 25:32Speaker 2: Yeah, so this is an area where I think it's
- 25:34Speaker 2: really important to defer to people who are actively providing treatment.
- 25:39Speaker 2: And you know, if you if you talk to addiction
- 25:41Speaker 2: medicine providers in the real world, one of the things
- 25:44Speaker 2: that they will continuously affirm is that they are needing
- 25:47Speaker 2: to use higher doses. But at the same time, I
- 25:50Speaker 2: think it's important to be responsive to the patient and
- 25:54Speaker 2: I think that that's something that providers get, and so
- 25:57Speaker 2: I'm a huge opponent of the FDA provide more flexible
- 26:01Speaker 2: labeling for buper and orthan products and potentially for methodone
- 26:05Speaker 2: as well, although we haven't seen as many changes in
- 26:09Speaker 2: the labeling for methadone products, but at least that I'm
- 26:11Speaker 2: aware of. But I think providing flexibility for buper and
- 26:15Speaker 2: orthan is very important because we need to give providers
- 26:18Speaker 2: the ability to use the dose they need, and we're
- 26:21Speaker 2: seeing higher dose is used, I think predominantly due to
- 26:26Speaker 2: the availability and expansion of fencenol and our drug supplies,
- 26:31Speaker 2: and we're seeing patients with just much more tolerance when
- 26:33Speaker 2: they're starting treatment and ergo higher amounts of measurable withdraw
- 26:37Speaker 2: and so we need to be able to respond to
- 26:39Speaker 2: that by using vupern orthan, you know, up to thirty
- 26:41Speaker 2: two milligrams or maybe beyond. At the same time, though,
- 26:45Speaker 2: I've also spoken to a lot of patients who said,
- 26:47Speaker 2: you know, my provider wants me to take sixteen, I
- 26:50Speaker 2: feel totally out of it, totally sedated on sixteen. I
- 26:53Speaker 2: want to go down to twelve. And there needs to
- 26:55Speaker 2: be space in the room for that perspective to be
- 26:57Speaker 2: heard as well, and there needs to be the flex
- 27:00Speaker 2: ability to allow a patient to express that they feel
- 27:03Speaker 2: like they are not really able to maximize the utility
- 27:07Speaker 2: of treatment because of the way that treatment is making
- 27:09Speaker 2: them feel, and so having permission to go up and
- 27:12Speaker 2: above and beyond twenty four I think is great. But
- 27:15Speaker 2: we also need to keep it in mind that some patients,
- 27:18Speaker 2: particularly those coming from prescription opioids or with a history
- 27:21Speaker 2: of creative use, although that is somewhat controversial, I suppose,
- 27:25Speaker 2: or those who are coming from you know, more sporadic
- 27:28Speaker 2: use of opioids prior, they may not need twenty four
- 27:32Speaker 2: and it's okay to end a stabilization knows at twelve
- 27:37Speaker 2: or at sixteen, and we just have to respond to
- 27:39Speaker 2: the patient's withdraw symptomatology.
- 27:42Speaker 1: I really appreciate the balanced approach there, you know, the
- 27:45Speaker 1: up the down kind of all around. It's a topic.
- 27:49Speaker 1: The reason, one of the many reasons I ask actually
- 27:52Speaker 1: is it's something that I even struggled with or perhaps
- 27:55Speaker 1: even struggle with on this. You know, imaginary thresholds going
- 28:00Speaker 1: to say limits, but is what it is for what's
- 28:02Speaker 1: out there? But you know I've dug deeper to find
- 28:06Speaker 1: you know, those original studies or even you know, the
- 28:08Speaker 1: scans like the PET scans have shown receptor activity in
- 28:11Speaker 1: the in the CNS or brain specifically even of you know,
- 28:15Speaker 1: I'm bub and orphins utilized, and you know, once all
- 28:17Speaker 1: the receptors get at occupied, then hey, what's left? Right?
- 28:21Speaker 1: So that that's where we some of where we get
- 28:22Speaker 1: max dos is from originally. And then it dawned on
- 28:26Speaker 1: me one day it's you know, that questioning, not the
- 28:29Speaker 1: question of the authority, but just asking some questions. I
- 28:32Speaker 1: remember seeing the scans and it was like, okay, well
- 28:34Speaker 1: there's no more receptors left. You know, it's going to
- 28:37Speaker 1: very patient of patient. But if it's the sixteen twenty
- 28:39Speaker 1: four as you mentioned thirty two, like you know, there's
- 28:42Speaker 1: no more room at the end, right, But those scans,
- 28:46Speaker 1: the question, the big looming question would be was were
- 28:48Speaker 1: that was that an opioid naive patient or an opioid
- 28:51Speaker 1: tolerance patient because you know, jumping ship here, even going
- 28:54Speaker 1: over to like SSRIs or even SNRIs, the number and
- 28:59Speaker 1: bandwidth of receptors changes in our body over time. Just
- 29:04Speaker 1: using a different example, of course. But and that comes
- 29:07Speaker 1: into play, right. We just don't have that articulated and
- 29:10Speaker 1: studies just yet. But you know, no, in pharmacology, it's
- 29:14Speaker 1: like been there, done that. Let's not dance in the
- 29:15Speaker 1: end zone when figuring things out. But I hope to
- 29:18Speaker 1: see more on that coming in the future, of course.
- 29:21Speaker 2: And I think we can even take a page from
- 29:25Speaker 2: you know, other playbooks here as well. So if we
- 29:27Speaker 2: look at the treatment of nicotine used disorder in particular,
- 29:30Speaker 2: one of the approaches to nicotine replacement therapy that is
- 29:34Speaker 2: actually most effective is to start the NRT a couple
- 29:37Speaker 2: of days before the patient stops smoking, right, So we
- 29:39Speaker 2: slap on a patch and tell them to smoke because
- 29:41Speaker 2: they want for about a week or so. And the
- 29:44Speaker 2: whole idea is that we are super saturating those receptors
- 29:47Speaker 2: with nicotine, and then we start to see extinction of
- 29:49Speaker 2: dry to consume. And you know, there's no doubt in
- 29:53Speaker 2: my mind that using a twenty one milligram patch and
- 29:57Speaker 2: telling somebody to continue smoking, there's no doubt my mind
- 30:00Speaker 2: that we are delivering too much nicotine. And and but still,
- 30:04Speaker 2: I think that idea of oversaturating those receptors and allowing
- 30:08Speaker 2: or maximizing circulating nicotine does sort of lead to those
- 30:12Speaker 2: behavioral modifications on their own and makes actual discontinuation of
- 30:16Speaker 2: smoking easier. And and you know, you're the you're more
- 30:19Speaker 2: of the pharmacologists than I am. But I see this
- 30:22Speaker 2: as a similar paradigm where as long as we're not
- 30:25Speaker 2: sedating the patient and as long as we're not causing harm,
- 30:29Speaker 2: we may as well try to optimize therapy by ensuring
- 30:34Speaker 2: that we've achieved as much receptor saturation as possible. Does
- 30:37Speaker 2: that make sense?
- 30:38Speaker 1: Yeah? Geez, I mean, I mean, where where where did
- 30:41Speaker 1: I get this guy? You're saying, do no harm. It's
- 30:43Speaker 1: like the charge of everyone cheese.
- 30:46Speaker 2: All right.
- 30:46Speaker 1: We we went pretty deep there into some of the
- 30:49Speaker 1: uh pharmacological aspects there with pupe and orphine. So let
- 30:53Speaker 1: me let me pull us back here. Okay, two questions
- 30:57Speaker 1: I ask every pain podcust first, one batter up here. So, Tyler,
- 31:02Speaker 1: how do you define pain? That's a great question.
- 31:07Speaker 2: I define pain, and this is not a very academic definition,
- 31:12Speaker 2: I guess, but I define pain as a sensation that
- 31:14Speaker 2: something is wrong that interferes with your ability to function,
- 31:18Speaker 2: you know, and and to me, this definition almost needs
- 31:23Speaker 2: to be very patient centered and is going to differ
- 31:25Speaker 2: dramatically between patients and what you feel may interfere with
- 31:29Speaker 2: your life. I may, I may not understand that. But
- 31:32Speaker 2: we have to listen to patients first when we're thinking
- 31:35Speaker 2: about what pain is to them, and ensure that we're
- 31:37Speaker 2: responsive to their needs. That's that's kind of my goal
- 31:40Speaker 2: with pain.
- 31:41Speaker 1: I suppose sounds like you're a huge fan of the
- 31:43Speaker 1: one to ten scale, and give me a number. Come on, man,
- 31:46Speaker 1: give me a number. Right, I'm being beyond facetious here.
- 31:50Speaker 2: Definitely all I.
- 31:53Speaker 1: Love it though. All right, the follow up one here,
- 31:55Speaker 1: since she sent you diagnosed it, what's your favorite pain medication.
- 31:59Speaker 2: Man, that's great question, And so I don't have a
- 32:03Speaker 2: lot of favorite medications, but I did think about this
- 32:06Speaker 2: because I knew it was coming. And you know, for myself,
- 32:11Speaker 2: my favorite antalgesic is good old fashioned ivy profit It's
- 32:14Speaker 2: not the only one that I take. But that being said,
- 32:17Speaker 2: I'm gonna I'm going to just use the context of
- 32:20Speaker 2: today's conversation and I'm going to say that buper and
- 32:22Speaker 2: orphan is my favorite analgesic. And the reason I'm going
- 32:25Speaker 2: to say that is because, first of all, it's widely
- 32:28Speaker 2: used in Europe in particular as an analgesic, and it's
- 32:31Speaker 2: been shown to be very effective for patients, especially who
- 32:35Speaker 2: don't respond well to weak opioids. But the other reason
- 32:38Speaker 2: that I think it's important to highlight the analgesic capacity
- 32:41Speaker 2: of buper and orthan is that one of the concerns
- 32:44Speaker 2: for patients that are starting treatment with buper and orthan
- 32:46Speaker 2: is that they will be in pain or experience pain
- 32:48Speaker 2: associated with with with withdrawal or transitioned to agonist therapy.
- 32:54Speaker 2: And I think that it's a really important counseling point
- 32:56Speaker 2: to deliver to these patients that buper and orthan is
- 32:59Speaker 2: a great treatment for pain and does lead to satisfactory
- 33:03Speaker 2: analgesia for patients with chronic painful conditions. And so while
- 33:07Speaker 2: I'm not, you know, rushing to make us pivot all
- 33:11Speaker 2: of our opioid pharmacotherapy to be bupron orphan based, I
- 33:14Speaker 2: do think it's an important tool in the tool chest
- 33:16Speaker 2: for pain.
- 33:18Speaker 1: So you went from ibuprofen, we will say OTC to
- 33:21Speaker 1: be pnorphine. I feel like in between there, you're like, hey,
- 33:24Speaker 1: why don't we make it OTC?
- 33:25Speaker 2: No, I know, I know, no, not gonna say that.
- 33:30Speaker 1: Yeah, we we got to keep our we got to
- 33:32Speaker 1: keep our pharmacology expertise rocking there too as well. So
- 33:37Speaker 1: thank you very much Tyler for that. It's and you know,
- 33:40Speaker 1: kind of doubling down on that too. I know you mentioned, hey,
- 33:43Speaker 1: there's a lot more products and studies that are out
- 33:47Speaker 1: there internationally when it comes to be p orphine for pain. Uh,
- 33:50Speaker 1: but you know, even right here in our own country,
- 33:52Speaker 1: we have multiple products, uh, and you know a decent
- 33:56Speaker 1: amount of studies out there as well too. And it
- 33:58Speaker 1: really is, you know, there's a difference between microgram and
- 34:01Speaker 1: milligram that's not even a p one thing that's like
- 34:04Speaker 1: mentally right, we we if as long as we teach it,
- 34:07Speaker 1: they can understand it really important in the big picture overall.
- 34:12Speaker 1: A couple I think it was years ago, actually I
- 34:14Speaker 1: pontificated on LinkedIn. I do that a decent amount, I guess,
- 34:18Speaker 1: And I asked people like, hey, what's your go to
- 34:20Speaker 1: prescription opioid? You know, all things aside, you know, like
- 34:23Speaker 1: pick something simple what you and everybody you know went
- 34:27Speaker 1: with the cop out responses of like, oh, it depends
- 34:30Speaker 1: on the scenario, and I'm like, no, like healthy individual.
- 34:32Speaker 1: You got a young guy just hurt himself, and it's
- 34:34Speaker 1: it's lingering what you can use, what you know, what's
- 34:37Speaker 1: the recommendation? And no one can handle that. And my mind,
- 34:41Speaker 1: I'm working on something. I got something in the oven
- 34:44Speaker 1: to kind of address some of that. And you know,
- 34:46Speaker 1: the overall opioid story for us here, So stay tuned
- 34:49Speaker 1: pain Pod Nation, but here today though, Tyler, really want
- 34:53Speaker 1: to thank you. It's it's always a pleasure, whether whether
- 34:55Speaker 1: we're recording our chats or not, but always a pleasure.
- 34:59Speaker 1: I really want to thank you your time and coming
- 35:00Speaker 1: on the pain Pod here today.
- 35:02Speaker 2: Thanks so much, Mark. This was great I appreciate all
- 35:05Speaker 2: you do and I hope that we can continue to
- 35:09Speaker 2: engage engage pharmacists and pain and addiction. I think it's
- 35:12Speaker 2: a great space for them, Ben, and I appreciate.
- 35:14Speaker 1: Your efforts likewise. And hey, it's all about conversations, right,
- 35:18Speaker 1: whether it's at a conference, whether you well here, I
- 35:21Speaker 1: guess it's one way. Folks are going to be listening
- 35:22Speaker 1: to this conversation. But you know, in reality, it's all
- 35:25Speaker 1: about the conversations we have all across the country. We
- 35:28Speaker 1: need to have more of those. Let's make them non circular,
- 35:31Speaker 1: Let's make them get somewhere and you know, come to
- 35:33Speaker 1: fruition for helping our patients. So Pain pot Nation, thank
- 35:37Speaker 1: you very much for your time. As always, I wish
- 35:40Speaker 1: you a great day every day and see you next
- 35:42Speaker 1: time on the Pain Pod.
- 35:44Speaker 3: If you'd like to join Mark on the Pain Pod,
- 35:47Speaker 3: send us an email to publish you're at Pharmacy podcast
- 35:50Speaker 3: dot com and make sure to share the show and
- 35:54Speaker 3: subscribe on your favorite podcast directory.
- 35:57Speaker 1: Thanks for listening.